Compare Brown-Forman Corporation Class B (BF.B) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Intuitive Surgical, Inc. — how do they compare? Brown-Forman Corporation Class B trades at $27.96, while Intuitive Surgical, Inc. trades at $402.08 (market cap $141.75B). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| BF.B | ISRG | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $592.85 |
52-Week Low | $22.80 | $332.02 |
Market Cap | — | $141.75B |
Enterprise Value | — | $136.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brown-Forman Class B (BF.B) trades at $28.03, down 0.57% on the day. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent earnings have beaten expectations in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is mixed, with a 25% buy rating amid divided coverage.
The outlook is cautiously optimistic given earnings momentum, but risks include competitive pressures and market volatility. Investment appeal hinges on sustained profit growth, though the lack of clear valuation metrics and mixed analyst views suggest a balanced risk-reward profile for investors.
Intuitive Surgical (ISRG) trades at $403.95, up 2.69% on the day, reflecting strong momentum. The stock exhibits bullish technical signals with support at $398 and resistance at $403. Fundamentally, revenue grew to $10.06B in 2025 with a net income margin of 28.45%, though valuation ratios like a P/E of 46.01 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.80 exceeding expectations. News highlights analyst upgrades and robust adoption of the da Vinci 5 system.
Outlook remains positive driven by innovation and market expansion, but high valuation and competitive pressures pose risks. The consensus price target of $518.10 implies significant upside, supported by 68% buy ratings from analysts. Key risks include reliance on U.S. procedure growth and rising competition from Medtronic and Johnson & Johnson. Long-term growth prospects appear solid if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
